APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

A multi-center, open-label, dose-finding study of five dose levels of APVO436 in combination with venetoclax and azacitidine (ven/aza) in adult patients with newly diagnosed, CD123+ AML.

Trial Details

NCT ID
NCT06634394
Phase
PHASE1
Sponsor
Aptevo Therapeutics
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • APVO436
  • Venetoclax
  • Azacitidine
Locations (sample)
  • Denver, Colorado, United States|39.73915,-104.9847
  • Miami, Florida, United States|25.77427,-80.19366
  • Fairway, Kansas, United States|39.02223,-94.6319
  • Canton, Ohio, United States|40.79895,-81.37845
  • Cincinnati, Ohio, United States|39.12711,-84.51439

Key Eligibility Criteria

  • 1\. Age ≥18 years. 2. Patient must have confirmation of AML based on 2016 World Health Organization (WHO) criteria and not been previously treated.
  • 3\. Patients must have CD123-positive AML as confirmed by local flow cytometry (or immunohistochemistry \[IHC\]). Confirmation at diagnosis is acce…
  • 4\. Patient must be considered ineligible for induction therapy defined by at least one of the following:
  • ≥75 years of age

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →